Sarlós Patrícia, Bikar Alexander, Borbásné Farkas Kornélia, Resál Tamás, Szepes Zoltán, Farkas Klaudia, . . . Molnár Tamás. (2023). Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: Results of a multicenter survey.
Chicago Style (17th ed.) CitationSarlós Patrícia, et al. Self-reported Efficacy and Safety of Infliximab and Adalimumab Biosimilars After Non-medical Switch in Patients with Inflammatory Bowel Disease: Results of a Multicenter Survey. 2023.
MLA idézésSarlós Patrícia, et al. Self-reported Efficacy and Safety of Infliximab and Adalimumab Biosimilars After Non-medical Switch in Patients with Inflammatory Bowel Disease: Results of a Multicenter Survey. 2023.